Loading...
XTSX
GENX
Market cap817kUSD
, Last price  
CAD
Name

Genix Pharmaceuticals Corp

Chart & performance

D1W1MN
XTSX:GENX chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
3.57%
Rev. 5Y
-50.58%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
-100.00%
818,258200,513223,180407,265282,803573,284603,109595,004373,132650,859924,6961,010,508419,960137,39600012,3474,0510
Net income
-335k
L+357.69%
-351,863-183,899-24,058-68,926-159,972-2,113-87,965-193,37131,667-545,984-129,048-243,206134,071-164,701-718,663-1,652,516-1,073,998-4,395,574-73,196-335,009
CFO
-124k
L-33.78%
46,991-145,055-102,0492,659-151,53047,961-278,948-244,597179,435-452,548-165,067-9,35134,177-58,550-195,034-428,312-219,578-220,674-187,340-124,052

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genix Pharmaceuticals Corporation, established in 1993 and headquartered in Vancouver, Canada, is actively involved in the creation, production, licensing, and distribution of various life science products. The company's primary focus in the Canadian market is on nutraceuticals and pharmaceuticals. Their product pipeline features several key developments: Flu-X: An herbal treatment available as an oral solution or spray, targeting viral infections, influenza, and coronaviruses responsible for common colds. Renochlor: A nutritional supplement formulated to support the revitalization and maintenance of kidney health and function. Sucanon: An insulin sensitizer designed to reduce blood sugar by improving the sensitivity of muscle, fat, and liver cells to insulin. Beyond these, Genix Pharmaceuticals also offers a wide range of other nutraceuticals and pharmaceutical items. This selection includes supplements such as bee propolis capsules, liquid calcium softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, alongside ophthalmic products like eye ointments and drops. The company operated under the name Alta Natural Herbs & Supplements Ltd. until it adopted its current identity, Genix Pharmaceuticals Corporation, in June 2019.

Key people

Chief Executive Officer · since 2019
Jianfang Jin
President, Secretary · since 2019
Jamie A. Lewin
Chief Financial Officer, Director · since 2019
Conny Lin
Director · since 2019
William Xiong
Independent Director · since 2007
IPO date
Jun 25, 1996
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑102024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT